

Wakelee, Heather

Institution/Organization

Stanford University and Stanford Cancer Institute

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

Understood

Disclosure of Potential Conflicts

Understood

COI Disclosure

Enter disclosures directly into the disclosure form.

Disclosures

AstraZeneca: Participated in advisory board in 2020, Local PI of clinical trial

Janssen: Advisory; board

Daiichi Sankyo: Advisory board

Blueprint: Advisory board

Mirati: Advisory role

Fishawack: Facilitate LTD Ongoing series of lectures

Medscape AND Research to Practice AND Curio Science: Multiple CME events

MJH holdings (PER): Multiple CME events/conferences; Participation in multiple CME lecture events and as chair of annual conference

UpToDate: Royalty payments

Axis Medical Education and Nexus Oncology: CME events

ACEA Biosciences: Local PI on trial

Arrys Therapeutics: Local PI of trial

BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene

Clovis Oncology: Local PI of trial

Genentech/Roche: Local PI of trial and Steering Committee Member

Merck: Local PI of trial and Steering Committee Member

Novartis: Local PI

Xcovery: Local PI of trial and Steering Committee Member

Seagen: Local PI of trial

Helsinn: Local PI of trial

Nexus Oncology: Gave CME lecture

COI Disclosure Certification

Disclosed

Confidentiality Agreement

Agree

Standards of Conduct Agreement

Agree

IASLC's Tax-Exempt Status

Agree

COI Follow-Up

Disclose any clinical trials you are conducting for institution fees.

I am conducting multiple ongoing studies (of note some of the conflicts disclosed above are for trials which are no longer open so not all listed conflicts on first page are reflected here):

Genentech/Roche - IMpower010

Helsinn - next generation selective RET inhibitor trial Merck- 671 neo-adjuvant pembro

Seagen - Institutional PI for phase I trial of novel ADC Xcovery - compassionate use study of ensartinib
Also institutional PI for several ECOG-ACRIN trials

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Executive Committee of ECOG-ACRIN Conference Chair PER ILCC annual meeting

Have you received any personal fees from any outside accreditation entities such as CME companies?

Yes, disclosed on first page.

Are you conducting clinical trials with any oncology equipment companies?

No